Praxis Precision Medicines マネジメント
マネジメント 基準チェック /44
Praxis Precision Medicinesの CEO はMarcio De'Souzaで、 Apr2020年に任命され、 の在任期間は 6.42年です。 の年間総報酬は$ 8.71Mで、 7.6%給与と92.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.003%を直接所有しており、その価値は$ 217.85K 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と4.9年です。
主要情報
Marcio De'Souza
最高経営責任者
US$8.7m
報酬総額
| CEO給与比率 | 7.57% |
| CEO在任期間 | 6.4yrs |
| CEOの所有権 | 0.003% |
| 経営陣の平均在職期間 | 5.3yrs |
| 取締役会の平均在任期間 | 4.9yrs |
経営陣の近況
Recent updates
Seeking Alpha • Sep 12
Praxis Precision Medicines: Still Potential Upside After Huge Rally (Rating Upgrade)
Summary Praxis Precision Medicines has surged over 1,000% since April 2025, driven by pivotal clinical wins for ulixacaltamide and relutrigine. Ulixacaltamide and relutrigine, both with 2026–2027 PDUFA dates, target large, underserved CNS markets with combined peak sales potential exceeding $15 billion. PRAX's $1.4 billion cash position supports a commercial buildout and reduces near-term capital market risk, with further upside from potential out-licensing and priority review vouchers. Despite the meteoric share run, PRAX retains significant upside, justifying a small investment, with covered calls offering an attractive entry strategy. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 22
PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts have lifted the fair value estimate for Praxis Precision Medicines to $188 from $162, reflecting higher modeled revenue potential for its late stage epilepsy and essential tremor programs, partially offset by a higher discount rate, slightly lower profit margin assumptions, and a richer future P/E multiple. Analyst Commentary Recent Street research on Praxis Precision Medicines shows a wide spread in price targets and views, with several firms highlighting both upside scenarios around epilepsy and essential tremor assets and execution risks tied to clinical outcomes and commercialization.
ナラティブ更新 • Aug 08
PRAX: Essential Tremor Launch Prospects Will Drive Future Upside Despite Seizure Trial Uncertainty
Praxis Precision Medicines enters this Narrative Update with the analyst price target higher in absolute dollar terms, supported by research that reflects revised fair value estimates, updated discount rates, refreshed revenue and margin assumptions, and a lower future P/E multiple in response to recent trial outcomes and pipeline commentary. Analyst Commentary Recent research on Praxis Precision Medicines presents a mixed picture, with several firms adjusting price targets and updating models after clinical readouts and management commentary.
ナラティブ更新 • Jul 24
PRAX: Late Stage Neurology Pipeline Will Drive Future Upside Potential
The analyst price target for Praxis Precision Medicines moved from $843 to $1,201, with analysts pointing to potential approvals for ulixacaltamide and relutrigine, along with ongoing interest in the broader late stage pipeline as key reasons for their updated assumptions. Analyst Commentary Recent Street research on Praxis Precision Medicines reflects a wide range of views, but several bullish analysts highlight what they see as meaningful upside tied to the company’s late stage neurology pipeline.ナラティブ更新 • Jul 10
PRAX: Vormatrigine Trial Setbacks Will Drive Future Repricing Risk
Analysts now place a $162.00 price target on Praxis Precision Medicines, adjusted from an earlier fair value estimate of about $85.76. This reflects updated views on discount rate, revenue growth potential, profit margins, and future P/E assumptions following recent trial outcomes and broader Street research.ナラティブ更新 • Jun 26
PRAX: Ulixacaltamide Tremor Opportunity Will Drive Future Upside Despite Vormatrigine Setback
Analysts have lifted their blended price target on Praxis Precision Medicines to about $618 from roughly $449, reflecting updated assumptions for ulixacaltamide's multi billion dollar sales potential in essential tremor and a lower, but still present, probability of success for vormatrigine after the POWER1 miss and POWER2 pause. Analyst Commentary Street research on Praxis Precision Medicines is split between enthusiasm for the ulixacaltamide opportunity and caution around execution risk after the POWER1 outcome for vormatrigine.Seeking Alpha • Mar 04
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Summary Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrigine (focal epilepsy) and relutrigine (SCN2A/SCN8A-DEEs). Vormatrigine must differentiate from Xcopri and XEN1101 in a highly competitive focal epilepsy market. Relutrigine showed promising seizure reduction in rare pediatric epilepsies but needs confirmation in larger pivotal trials. Praxis has $400M+ cash, funding operations into 2028, with key epilepsy trial readouts expected in 2H 2025. Read the full article on Seeking AlphaSeeking Alpha • Dec 26
Praxis Precision Medicines: Multiple Potential Drivers
Summary Praxis Precision Medicines, Inc., a promising clinical stage biopharma concern, has seen significant stock gains in the second half of 2024. Analyst firms are quite bullish on the stock, with eight firms recently issuing Buy ratings and price targets ranging from $114 to $305 per share. The company has several potential drivers with its late-stage pipeline candidates and possesses a decent balance sheet. While the stock should only be considered by aggressive investors given its recent rally, I have taken a small position in PRAX stock via covered call orders. An analysis around Praxis Precision Medicines follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 13
Praxis Precision Medicines: Great Price Movement, But Still Not Convinced
Summary Praxis Precision Medicines has shown impressive growth, but past trial failures and current risks warrant caution before investing. The lead candidate, Ulixacaltamide, is in a phase 3 trial for essential tremor, with results expected by the end of 2024. PRAX-628 shows promise for epilepsy, but the small patient cohort and competitive landscape raise concerns. Despite significant stock gains, I remain unconvinced and seek more data before making an investment decision. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$339m |
| Mar 31 2026 | n/a | n/a | -US$327m |
| Dec 31 2025 | US$9m | US$659k | -US$303m |
| Sep 30 2025 | n/a | n/a | -US$273m |
| Jun 30 2025 | n/a | n/a | -US$251m |
| Mar 31 2025 | n/a | n/a | -US$213m |
| Dec 31 2024 | US$13m | US$640k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$151m |
| Jun 30 2024 | n/a | n/a | -US$124m |
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$625k | -US$123m |
| Sep 30 2023 | n/a | n/a | -US$138m |
| Jun 30 2023 | n/a | n/a | -US$157m |
| Mar 31 2023 | n/a | n/a | -US$183m |
| Dec 31 2022 | US$6m | US$625k | -US$214m |
| Sep 30 2022 | n/a | n/a | -US$231m |
| Jun 30 2022 | n/a | n/a | -US$232m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$11m | US$571k | -US$167m |
| Sep 30 2021 | n/a | n/a | -US$135m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$88m |
| Dec 31 2020 | US$12m | US$385k | -US$70m |
報酬と市場: Marcioの 総報酬 ($USD 8.71M ) は、 US市場 ($USD 8.47M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Marcioの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Marcio De'Souza (47 yo)
6.4yrs
在職期間
US$8,708,648
報酬
Mr. Marcio Silva De'Souza M.B.A., has been President, Chief Executive Officer and Director of Praxis Precision Medicines, Inc. since April 2020. Mr. De'Souza joined the Praxis Precision Medicines, Inc. in...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.4yrs | US$8.71m | 0.0026% $ 217.8k | |
| CFO & Treasurer | 5.3yrs | US$3.20m | 0.033% $ 2.7m | |
| General Counsel & Secretary | 6.3yrs | US$2.84m | 0.024% $ 2.0m | |
| Co-Founder and President of Research & Development | no data | データなし | データなし | |
| Chief Operating Officer | less than a year | データなし | 0.024% $ 2.0m | |
| Chief Technical Operations Officer | 4.8yrs | データなし | データなし | |
| Chief People Officer | 5.8yrs | データなし | 0.013% $ 1.1m | |
| Chief Regulatory & Quality Officer | 6yrs | データなし | データなし | |
| Chief of Staff | 4.5yrs | データなし | データなし | |
| Head of Clinical Strategy | less than a year | データなし | データなし |
5.3yrs
平均在職期間
49yo
平均年齢
経験豊富な経営陣: PRAXの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.4yrs | US$8.71m | 0.0026% $ 217.8k | |
| Independent Director | 9.8yrs | US$418.72k | 0.0068% $ 567.6k | |
| Independent Chairman of the Board | 6yrs | US$445.22k | 0.062% $ 5.2m | |
| Independent Director | 7.5yrs | US$426.22k | 0.00067% $ 55.9k | |
| Independent Director | 5.4yrs | US$416.72k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$421.22k | 0.0084% $ 698.6k | |
| Independent Director | 5.4yrs | US$412.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Chairman of the Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし |
4.9yrs
平均在職期間
69yo
平均年齢
経験豊富なボード: PRAXの 取締役会 は 経験豊富 であると考えられます ( 4.9年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 13:15 |
| 終値 | 2026/09/18 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Praxis Precision Medicines, Inc. 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29
| アナリスト | 機関 |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |